Page 1

ASX Release SUDA PHARMACEUTICALS LTD ACN 090 987 250 Appendix 4C : Third Quarter FY 2021 Activities Report PERTH , AUSTRALIA - 27 April 2021 : SUDA Pharmaceuticals Ltd ( ASX : SUD ) , a leader in oro- mucosal drug delivery , today released its Appendix 4C for the consolidated group for the third quarter of FY 2021 . Highlights ● End of period cash balance of $ 4.28m . • Following a review of operations , the Company created efficiencies for ongoing formulation development work . • SUDA has contracted the services of MedPharm to assist with formulation development for anagrelide , which is being developed as an adjunct therapy for metastatic disease . • SUDA added two world renowned experts to its Scientific Advisory Board . • Management continued to source and evaluate new technologies to strengthen the Company's pipeline . During the quarter ended 31 March 2021 , the Company was pleased with the following developments : ● SUDA has contracted the services of MedPharm , who will perform formulation development work and provide valuable expertise , assisting to stabilise and optimise the oral spray formulation for anagrelide . MedPharm is a world - leading Contract Development and Manufacturing Organisation ( CDMO ) that focus on topical and transdermal product design and development services and they have played a role in the development of 55 approved pharmaceutical products . • SUDA made two important appointments to its Scientific Advisory Board ; Professor Anil K. Sood , MD and Professor Gunnar Birgegård , MD , PhD . 27 April 2021 Page 1 of 3